reports
Melinta Therapeutics Announces Termination of Merger Agreement and Ten...
Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase MORRISTOWN, N.J., June 24, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 24, 2020, pursuant to the Agreement and Plan of Merger by and among Melinta, Toronto Transaction Corp. (“Purchaser”) and Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) dated as of June 4, 2020 (the “Merger Agreement”), it had terminated the previously announced cash tender offer to acquire all of the outstanding shares of common sto...
Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharm...
Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals Company Enters Growth Phase in Hospital Market with Support of Deerfield Acquisition to Augment Company’s Core Antibiotic Portfolio MORRISTOWN, N. J. , June 09, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 4, 2020, it entered into a definitive merger agreement with Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) pursuant to which Melinta would acquire Tetraphase, through a tender offer, for an aggregate of $39.0 million ...
Melinta Therapeutics Confirms Deerfield as Successful Bidder for Compa...
Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company Company Poised to Emerge on Financially Sound Footing Ensuring Continued Availability of Company’s Products and Related Support MORRISTOWN, N.J., March 04, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, confirmed today that the Company’s agreement with funds managed by Deerfield Management Company, L.P., the lenders under the Company’s senior cred...
Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Pr...
Melinta Therapeutics Announces Court Approval of Chapter 11 Bidding Procedures Bids due on March 2, 2020 by 4:00 p.m. Eastern Time Company Previously Announced Agreement of its Secured Lenders to Acquire Company as Going Concern, Subject to Higher and Better Offers Company Continues Operations with No Anticipated Disruption to Product Supply or Support MORRISTOWN, N.J., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infe...
Melinta Therapeutics Announces Restructuring Support Agreement with it...
Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility Company Initiates Voluntary Chapter 11 Process to Effectuate Restructuring Transaction While Continuing Normal-Course Operations MORRISTOWN, N.J., Dec. 27, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT) (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that it has entered into a Restructuring Support Agreement (the “Ag...
Melinta Therapeutics Files Quarterly Report on Form 10-Q for the Quart...
Melinta Therapeutics Files Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2019 MORRISTOWN, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that it has filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2019 with the Securities and Exchange Commission (“SEC”). The Company encourages its current and potential investors to read this quarterly repor...
Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New D...
Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) ~ Approval Based on Positive Phase III Trial Results of BAXDELA for Treatment of CABP in Adults~ ~ Company Delays Launch of CABP Indication Until Further Visibility Into Liquidity Position ~ MORRISTOWN, N.J., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial in...
Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to I...
Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director MORRISTOWN, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (Nasdaq: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that Jennifer Sanfilippo has been named interim chief executive officer and director, effective August 28, 2019. Prior to this appointment, Ms. Sanfilippo served as senior vice president and general counsel of Melinta. “Jennifer’s a...
Melinta Therapeutics Names David Gill as Chairman and Announces CEO Su...
Melinta Therapeutics Names David Gill as Chairman and Announces CEO Succession Plan Company Initiates Search for New Chief Executive Officer MORRISTOWN, N.J., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced changes to its board of directors and executive management team. David Gill, a current Melinta board member, has been named chairman of the board of directors, effective immediately, succeeding Kevin Ferr...
Melinta Therapeutics Reports Second Quarter 2019 Financial Results and...
Melinta Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update ~ Revenue of $16.0 million, Including Net Product Sales of $13.8 million, for the Second Quarter 2019 ~ ~ Reduction of Operating Expenses of 32 Percent, or $16.3 million, Year-Over-Year ~ ~ Commenced Enrollment in Clinical Trial Evaluating Orbactiv® (oritavancin) Shorter Infusion Time Formulation in Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) ~ ~ First Commercial Sale of Baxdela® (delafloxacin) Outside of the United States ~ MORRIS...
Melinta Therapeutics Announces Rescheduling of Second Quarter 2019 Fin...
Melinta Therapeutics Announces Rescheduling of Second Quarter 2019 Financial Results Reporting ~ Second Quarter 2019 Financial Results to be Reported on Friday, August 9, 2019 ~ ~ Company Cancels Previously Scheduled Earnings Call ~ MORRISTOWN, N.J., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that it will report its second quarter 2019 financial results on Friday, August 9, 2019. The Company also announ...
Melinta Therapeutics Announces Preliminary Second Quarter 2019 Financi...
Melinta Therapeutics Announces Preliminary Second Quarter 2019 Financial Results and Provides Corporate Update ~ Expects to Report Second Quarter 2019 Net Product Sales of Approximately $13.8 Million, Which Represents an Increase of 17 Percent Over the First Quarter of 2019 ~ ~ Anticipates Having Approximately $90 Million of Cash and Cash Equivalents on Hand at the End of the Second Quarter 2019 ~ ~ Targeting Full-Year 2019 Operating Expense Reductions of Approximately $70 Million ~ ~ Plans to Report Final Second Quarter 2019 Financial Results on August 7, 2019 at 8:30 a.m. ET ~ MORRIS...
Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New...
Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia ~ Application Seeks to Expand Label to Include an Indication and Phase III Data for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia (CABP) ~ ~ PDUFA Date Set for October 24, 2019 ~ MORRISTOWN, N.J., June 19, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious...
Melinta Therapeutics Reports First Quarter 2019 Financial Results and ...
Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update ~ Revenue of $14.1 million, Including Net Product Sales of $11.8 million, for the First Quarter 2019 ~ ~ Reduction of Operating Expenses of 34 Percent, or $19.8 million, Year-Over-Year ~ ~ Filed Supplemental New Drug Application for Baxdela® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia ~ MORRISTOWN, N.J., May 09, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company, developing and commercializing novel antibi...
Melinta Therapeutics to Present at Making a Difference in Infectious D...
Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting MORRISTOWN, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, announced today that it will present data on its portfolio, including results from its real-world registry studies of VABOMERE® (meropenem and vaborbactam), ORBACTIV® (oritavancin), and MINOCIN® (minocycline) for Injection at the upcoming Making a Difference...
Melinta Therapeutics to Report First Quarter 2019 Financial Results on...
Melinta Therapeutics to Report First Quarter 2019 Financial Results on May 9, 2019 MORRISTOWN, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced it intends to release its first quarter 2019 financial results on May 9, 2019, after the close of the U.S. financial markets. Melinta will host a conference call and live webcast on Thursday, May 9, 2019, at 4:30 p.m. ET to discuss its financial results and provide...
Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financ...
Melinta Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results ~ Reports Revenue of $96.4 million, Including Net Product Sales of $46.6 million, for the Full-Year 2018 ~ ~ Net Product Sales of $14.6 million for the Fourth Quarter of 2018, up 32 Percent from Prior Quarter ~ ~ Corporate Milestones Across Commercial Operations, Clinical and Business Development Provide Critical Growth Opportunities ~ ~ Provides Guidance for 2019 ~ MORRISTOWN, N.J., March 13, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company, developing and c...
Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financ...
Melinta Therapeutics to Report Fourth Quarter and Year-End 2018 Financial Results on March 13, 2019 MORRISTOWN, N.J., March 05, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced it intends to release its fourth quarter and year-end 2018 financial results on March 13, 2019, after the close of the U.S. financial markets. Melinta will host a conference call and live webcast on Wednesday, March 13, 2019 at 4:30 p.m. ET to di...
Melinta Therapeutics Announces Closing of Initial $75 Million Vatera C...
Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding – Amendment to Deerfield Facility Agreement Becomes Effective – – John H. Johnson Appointed Permanent Chief Executive Officer – – Company to Report Fourth Quarter and Full Year 2018 Financial Results on March 13, 2019 – MORRISTOWN, N.J., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the closing and receipt of the...
Melinta Therapeutics Announces One-for-Five Reverse Stock Split
Melinta Therapeutics Announces One-for-Five Reverse Stock Split NEW HAVEN, Conn., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that its Board of Directors has approved a one-for-five reverse stock split of the Company's common stock, par value $0.001. The reverse stock split, which was approved by the Company's stockholders at a special meeting held on February 19, 2019, will be effective at 5:00 pm Eastern ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.